In December 2024, NICE recommended the use of tirzepatide (Mounjaro), alongside semaglutide (Wegovy) and liraglutide (Saxenda), for the treatment of weight-related comorbidities.10 NICE recommended these drugs alongside diet and exercise, yet many patients lack structured programs offering nutritional, behavioural, and psychological support
Semaglutide, by contrast, binds GLP-1 receptors in the brain and gut to reduce hunger signals, lower blood sugar, and promote satiety
This is the shift I want to examine
Luttinger et al., 1983)
Nagatsu T, Nakashima A, Ichinose H, Kobayashi K (2019) Human tyrosine hydroxylase in Parkinsons disease and in related disorders
Redox Biology 23, 101107